Sarepta Therapeutics, Inc. (SRPT) Stock Profile — Insider Trades & Financials

Revenue$369.6M

Net Income-$282.8M

EPS$-7.13

Market Cap$2.4B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Douglas S. Ingram

CEO & Executive Director

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.

Employees: 1,314
Headquarters: CAMBRIDGE, MA, United States
Website: www.sarepta.com

Peer ComparisonRevenue ($B)

▾

⚡

Core Efficiency

ROE?

-24.80%

ROA?

-8.44%

D/E Ratio?

1.94

Op. Margin?

-111.36%

📊

Profitability Ratios

Net Margin?

-76.53%

Loading company sections...

Sarepta Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness